Dendreon Corp fka DNDNQ

[ocyanblue]

<His letter seemed sincere, although some of the mistakes documented here and on IV raise questions about craftsmanship. I find it very hard to believe that he is being dishonest.>

See my post on iVillage 76998.
http://www1.investorvillage.com/smbd.asp?mb=971&mn=76998&pt=msg&mid=1902510

The confusion about the p value for DN-101 was probably genuine. However, it was a bit suspicious for him to point out the imbalances on soft tissue mets and GS while ignoring the imbalance on the number of bone mets which was highly predictive of mortality in both D9901 and D9902a and went against the treatment arm. In addition, he should have known about the 6% CVAs in the phase-2 trial of Tax and how that might have translated into the phase-3 trial even if they did not collect that data. For him to make a big deal on that about the Provenge trial and the comment on 20 years down the line on an old-man and fast terminal disease like AIPC was something else. I am rather surprised that somebody like him would write such a letter without vetting all the facts. Make one wonder what sort of pressure he has been in since the meeting, either internally or externally generated.